Physician profile
Erin Dunagan
NPI 1154187037
$1,451.42
in general payments reported to CMS, 2019-2025
10 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,120 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $361.85 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $259.10 | 2024-2025 | |
| Novo Nordisk INC | $189.52 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $145.64 | 2024-2025 | |
| Glaxosmithkline, LLC. | $139.03 | 2024 | Arexvy, Shingrix |
| Gilead Sciences, INC. | $125.00 | 2024 | Descovy |
| Pfizer INC. | $118.98 | 2024 | |
| Exact Sciences Corporation | $54.85 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $43.18 | 2025 | Invega Sustenna |
| Lilly USA, LLC | $14.27 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Dunagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.